Abstract: A roller bearing includes an outer ring, an inner ring, at least one row of rollers arranged between the outer ring and the inner ring, and at least one optical fiber cable mounted to the outer ring or the inner ring, the optical fiber cable including at least one Bragg grating. The optical fiber cable is configured such that a signal in the optical fiber cable is usable to determine a preload or load on the roller bearing.

Abstract: A method of identifying an SCLC patient at risk of disease progression comprising determining the expression of at least one marker selected from a neuroendocrine marker and/or DLLS in a blood sample or blood sample fraction of said patient, wherein said at least one marker is indicative of the patients prognosis.

Abstract: A roller bearing includes an outer ring, an inner ring, at least one row of rollers arranged between the outer ring and the inner ring, and at least one optical fiber cable mounted to the outer ring or the inner ring, the optical fiber cable including at least one Bragg grating. The optical fiber cable is configured such that a signal in the optical fiber cable is usable to determine a preload or load on the roller bearing.

Abstract: A method of determining ovarian cancer disease in a subject, which comprises—measuring the PPIC expression of cells in a sample of peripheral blood of said subject, and—comparing to a reference value, the PPIC overexpression being indicative of a ovarian cancer disease and/or disease progression, and the use of such a method for the diagnosis of ovarian cancer or a method for the determination of the metastatic potential in an ovarian cancer patient at risk of disease progression.

Abstract: A method of determining CCNE2 in a body fluid sample of patients at risk for solid tumor disease. A multi-marker panel is preferably used for detecting circulating tumor cells, comprising CCNE2, DKFZp762E1312, EMP2, MAL2, PPIC, SLC6A8 and GTF2IRD1, and optionally further comprising one or more markers from the group consisting of AGR2, FXYD3, S100A16, TFF1, mammaglobin A, FN, Epcam, tm4sf and rbpms.

Abstract: A non-invasive method for the diagnosis of adenocarcinoma or precursor lesions in a female subject and a kit for performing such diagnosis are provided. The method comprises the steps of (1) preparing epithelial cells of a sample of the subject obtained from a rinse of the uterine cavity and, optionally, the fallopian tubes, and (2) performing an analysis of the cells to determine an abnormality associated with ovarian or endometrial cancer, where the abnormality is indicative of adenocarcinoma or a precursor lesion.

Abstract: The invention is directed to a method of diagnosing a malignant ovarian tumor disease in a subject, which comprises —providing a sample of peripheral blood cells (PBC) of the subject, —measuring the expression of a multimarker gene panel comprising at least NEAT1, BC037918, C1 orf63, PRIC285, OSM, and optionally further genes or protein markers, and —comparing to a reference value, the differential expression being indicative of a malignant ovarian tumor, and a set of reagents to determine the expression of such a multimarker panel, as well as the use of a PBC-expression based test to improve the diagnosis of ovarian cancer. The invention further relates to a method of determining the expression of at least one of the RPL21, RPL9 and/or SH3BGRL3 genes in a PBC sample of a subject as internal control.

Abstract: A method of determining gynaecologic tumor disease in a subject by providing a sample of peripheral blood of the subject, measuring the PPIC expression of cells in the sample, and comparing this to a reference value, the PPIC overexpression being indicative of a gynecologic tumor disease and/or disease progression, including metastatic potential in a gynecologic cancer patient.

Abstract: A method of determining CCNE2 in a body fluid sample of patients at risk for solid tumor disease. A multi-marker panel is preferably used for detecting circulating tumor cells, comprising CCNE2, DKFZp762E1312, EMP2, MAL2, PPIC, SLC6A8 and GTF2IRD1, and optionally further comprising one or more markers from the group consisting of AGR2, FXYD3, S100A16, TFF1, mammaglobin A, FN, Epcam, tm4sf and rbpms.

Abstract: The invention relates to a method and a test kit for diagnosing ovarian cancer and/or making predictions in case of ovarian cancer as well as a method for estimating the effectiveness of therapeutic agents during the treatment of ovarian cancer, the promoter hypermethylation of the TUSC3 marker in a biological sample that is to be analyzed, preferably in a tissue sample or biological liquid that is to be analyzed, being measured. The result of said method can be used for planning an ovarian cancer treatment.